Moderna与Merck公司联合宣布，其个性化mRNA癌症疫苗intismeran（mRNA-4157）在黑色素瘤III期临床试验中取得成功12。该试验共纳入1,137名手术切除后的IIB-IV期黑色素瘤患者，按2比1的比例随机分配接受intismeran与Keytruda联合治疗或仅接受Keytruda治疗1。试验结果显示，联合用药组患者的无癌复发或转移生存期相比单独使用Keytruda组明显延长2。这标志着mRNA疫苗和个性化癌症靶向疗法在癌症治疗中首次取得成功1。
消息公布后，Moderna股价上涨超过120%至每股140.12美元，Merck股价上涨约11%2。两家公司计划在即将召开的国际医学会议上公布详细的研究结果2。
Moderna and Merck announced that their experimental personalized mRNA cancer vaccine has succeeded in a pivotal Phase 3 clinical trial for melanoma patients 12. The vaccine candidate, intismeran (mRNA-4157), was tested in combination with Merck's immunotherapy drug Keytruda against Keytruda alone in patients with surgically resected stage IIB–IV melanoma 1.
The trial enrolled 1,137 patients who were randomly assigned in a 2-to-1 ratio to receive either intismeran combined with Keytruda or Keytruda monotherapy 1. Patients receiving the combination therapy demonstrated extended recurrence-free or metastasis-free survival compared to those treated with Keytruda alone 2. This marks the first successful clinical outcome for an mRNA vaccine combined with a personalized cancer-targeting approach in cancer treatment 1.
The positive results triggered significant market response, with Moderna's stock price surging more than 120 percent to $140.12 per share, while Merck's shares rose approximately 11 percent 2. The companies plan to present detailed findings from the study at an upcoming international medical conference 2.
评论
还没有评论，欢迎留下第一条。